Brought to you by 
Impax, Shire settle litigation regarding Adderall XR
08 Feb 2013
Executive Summary
Shire Pharmaceuticals and Impax Laboratories (generics) have reached a settlement concerning the former's attention deficit hyperactivity disorder treatment Adderall XR. Under the agreement, Impax can sell a generic version of the drug in the US starting no later than January 1, 2010.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Impax, Shire settle litigation regarding Adderall XR
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice